Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bart Van Baelen"'
Publikováno v:
Journal of Alzheimer's Disease. 27:521-530
In Alzheimer's disease (AD), it is important to consider long-term effects, not only in patients receiving treatment, but also in subjects in whom therapy has been discontinued. The present analysis evaluates the long-term effects of galantamine on c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f5998550efabdb73657beefa9918f8
https://doi.org/10.3233/jad-2011-110417
https://doi.org/10.3233/jad-2011-110417
Autor:
Susanne Schwalen, Bart Van Baelen, Brian Everitt, Shane Kavanagh, Jean-François Dartigues, Tuula Pirttilä, Howard Feldman
Publikováno v:
International Journal of Geriatric Psychiatry. 24:479-488
Objective This study evaluated patient and treatment (galantamine and other acetylcholinesterase inhibitors (AChEIs)) factors associated with the time until nursing home placement (NHP) in patients with Alzheimer's disease (AD) with and without cereb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8692d8ef2a7ff36d7202b1e2a4d066c
https://doi.org/10.1002/gps.2141
https://doi.org/10.1002/gps.2141
Publikováno v:
Drugs & Aging. 26:231-239
Background: Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer’s type. Although several drugs are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::684a38a20f30238de441eee4ca445e92
https://doi.org/10.2165/00002512-200926030-00004
https://doi.org/10.2165/00002512-200926030-00004
Publikováno v:
Alzheimer Disease & Associated Disorders. 19:29-36
Placebo data were pooled from two 1-year, randomized, double-blind, placebo-controlled trials of sabeluzole in patients with mild-to-moderate Alzheimer disease (AD). Cognition was assessed using the Alzheimer's Disease Assessment Scale-cognitive subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5530b844bbf629a5eb47acafb6af77db
https://doi.org/10.1097/01.wad.0000157065.43282.bc
https://doi.org/10.1097/01.wad.0000157065.43282.bc
Autor:
Michael H. Davidson, Susanne Schwalen, Rafael Blesa, Alexander Kurz, William E. Reichman, Bart Van Baelen
Publikováno v:
Dementia and Geriatric Cognitive Disorders. 15:79-87
Galantamine (Reminyl®), a novel agent with a dual mode of action, modulates nicotinic acetylcholine receptors and inhibits acetylcholinesterase. Galantamine has consistently demonstrated a broad range of beneficial effects and has shown sustained be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99222ae1e3f5558fd0a9aa19a1e33df4
https://doi.org/10.1159/000067974
https://doi.org/10.1159/000067974
Publikováno v:
Alzheimer's & Dementia. 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe3d1f83f431ef04702a812ac9d44cb1
https://doi.org/10.1016/j.jalz.2011.05.2263
https://doi.org/10.1016/j.jalz.2011.05.2263
Publikováno v:
Alzheimer's & Dementia. 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::217f6d7638d3fd710ae76937c88e8e46
https://doi.org/10.1016/j.jalz.2011.05.1911
https://doi.org/10.1016/j.jalz.2011.05.1911
Autor:
Susanne Schwalen, Shane Kavanagh, Arnaud Foucher, Lutz Froelich, Bart Van Baelen, Niels Andreasen, Magda Tsolaki
Publikováno v:
Current medical research and opinion. 25(12)
The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer's disease (AD) on patient outcomes and caregiver burden in a real-life setting.This 2-year, international, prospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82ea887b0b2c228318f123e659350a60
https://pubmed.ncbi.nlm.nih.gov/19852697
https://pubmed.ncbi.nlm.nih.gov/19852697
Autor:
Joop van Oene, Roberto Bernabei, Christoph Hock, Alfonso J. Cruz Jentoft, Eric Triau, Roger Bullock, Susanne Schwalen, Bart Van Baelen, Alistair Burns, Gerry Hammond, Anders Wimo, Minna Raivio, Lutz Frölich, Maurits Vandewoude, Elizabeth Came
Publikováno v:
The lancet neurology
Summary Background The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer's disease (AD). Here we report its efficacy in patients with severe AD. Methods Between December, 2003, and March, 2007, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bfb1fd63fab3fc50aa805ae11ab2497
https://pubmed.ncbi.nlm.nih.gov/19042160
https://pubmed.ncbi.nlm.nih.gov/19042160
Publikováno v:
International journal of geriatric psychiatry. 18(10)
Aim The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers. Methods Data were pooled from two concurrent, multi-centre, randomized, double-blind, placeb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e9cf4f6bdab7da8193c982b54c3fe4
http://ora.ox.ac.uk/objects/uuid:0b281446-0f5a-4ebd-949e-b3f19c5b36eb
http://ora.ox.ac.uk/objects/uuid:0b281446-0f5a-4ebd-949e-b3f19c5b36eb